New systemic treatment options for advanced cholangiocarcinoma.

However, although a benefit in median PFS was observed, it did not reach statistical significance: median PFS was 6.5 months (95% CI, 5.7-6.9) in the experimental arm and 5.6 months (95% CI, 5.1- 6.6) in the control arm (HR, 0.86; 95% CI, 0.75-1.00; P =0.023).

also in 17,681 other papers